| SC 13D/A | 2015-05-26 | POLARIS VENTURE PARTNERS IV LP | ACCELERON PHARMA INC | 1,853,693 | 5.6% | EDGAR |
| SC 13D/A | 2015-02-17 | POLARIS VENTURE PARTNERS IV LP | ACCELERON PHARMA INC | 2,534,211 | 7.9% | EDGAR |
| SC 13G/A | 2015-02-17 | ADAGE CAPITAL PARTNERS GP LLC | ACCELERON PHARMA INC | 1,772,406 | 5.5% | EDGAR |
| SC 13G/A | 2015-02-17 | ORBIMED ADVISORS LLC | ACCELERON PHARMA INC | 0 | 0.0% | EDGAR |
| SC 13G/A | 2015-02-13 | PRICE T ROWE ASSOCIATES INC /MD/ | ACCELERON PHARMA INC | 3,411,375 | 10.5% | EDGAR |
| SC 13G/A | 2015-02-13 | FMR LLC | ACCELERON PHARMA INC | 4,837,978 | 15.0% | EDGAR |
| SC 13G/A | 2015-02-13 | VENROCK ASSOCIATES IV L P | ACCELERON PHARMA INC | 1,494,440 | 4.6% | EDGAR |
| SC 13G/A | 2015-02-12 | Applied Genomic Technology Capital Fund LP | ACCELERON PHARMA INC | - | - | EDGAR |
| SC 13G/A | 2015-02-10 | ADVANCED TECHNOLOGY VENTURES VII LP | ACCELERON PHARMA INC | 1,677,399 | 5.2% | EDGAR |
| SC 13G | 2015-02-06 | BlackRock Inc. | ACCELERON PHARMA INC | 1,632,581 | 5.1% | EDGAR |
| SC 13G | 2014-07-10 | PRICE T ROWE ASSOCIATES INC /MD/ | ACCELERON PHARMA INC | 3,271,727 | 10.4% | EDGAR |
| SC 13G | 2014-06-12 | ADAGE CAPITAL PARTNERS GP LLC | ACCELERON PHARMA INC | 1,600,469 | 5.1% | EDGAR |
| SC 13D/A | 2014-05-13 | POLARIS VENTURE PARTNERS IV LP | ACCELERON PHARMA INC | 2,950,013 | 9.5% | EDGAR |
| SC 13G/A | 2014-05-12 | FMR LLC | ACCELERON PHARMA INC | 4,206,928 | 13.4% | EDGAR |
| SC 13D/A | 2014-05-06 | CELGENE CORP /DE/ | ACCELERON PHARMA INC | 4,611,866 | 14.6% | EDGAR |
| SC 13D/A | 2014-04-07 | POLARIS VENTURE PARTNERS IV LP | ACCELERON PHARMA INC | 3,257,906 | 10.5% | EDGAR |
| SC 13D/A | 2014-04-02 | CELGENE CORP /DE/ | ACCELERON PHARMA INC | 3,511,866 | 11.3% | EDGAR |
| SC 13D | 2014-02-14 | POLARIS VENTURE PARTNERS IV LP | ACCELERON PHARMA INC | 3,257,906 | 10.6% | EDGAR |
| SC 13G | 2014-02-14 | FMR LLC | ACCELERON PHARMA INC | 1,803,400 | 6.4% | EDGAR |
| SC 13G | 2014-02-14 | VENROCK ASSOCIATES IV L P | ACCELERON PHARMA INC | 2,622,435 | 9.2% | EDGAR |